Sussex Research Laboratories Inc. receives Notice of Allowance for Glycopeptide Cosmetic Active technology patent
Share
Sussex Research Laboratories Inc. Laboratories Inc., the leading specialist in carbohydrate synthesis, glycosylation and glycodesign, is pleased to announce that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/103,452 entitled “GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF.” The patent covers the Company’s novel cosmetic active ingredient, GlycolastinTM, a glycosylated peptide developed as an anti-wrinkling cosmetic active that efficiently improves the appearance of fine lines and wrinkles while also increasing skin hydration and elasticity. In vitro studies have shown that GlycolastinTM stimulates at least 3 major constituents of skin that are all important for the maintenance of healthy skin. In vivo studies demonstrated that, within 42 days, crow’s feet wrinkles were visibly decreased while also improving skin hydration and elasticity.
Dr. Brady Clark, President and Chief Executive Officer stated: “This is the first of what we hope will be several patents that we expect to receive to protect our GlycolastinTM technology which utilizes glycosylation to improve the effectiveness of cosmetic peptide actives. We expect finished products that utilize this unique active to be introduced in 2018.”
About Glycolastin™
Glycolastin™has been developed by Sussex Research Laboratories Inc. to exploit the field of glycobiology in order to advance a new and state-of-the-art anti-aging technology. In vitro studies have shown that Glycolastin™ is significantly more efficient at stimulating structural protein synthesis in skin cells than the non-glycosylated peptide active, a well-known peptide active in the cosmetics field. Increased secretion of structural proteins elastin, fibronectin and collagens by fibroblasts was observed in vitro for glycosylated peptides compared to the non-glycosylated reference peptide. The in vitro effect on elastin secretion has also been confirmed independently in a 3D ex vivo skin model. Patents have been filled in numerous jurisdictions.